National Science Foundation

Amplified Sciences LLC is a molecular diagnostics company focused on the early detection of debilitating diseases, particularly pancreatic cancer and kidney disease. Utilizing an ultra-sensitive molecular sensing technology licensed from Purdue University, the company’s platform can detect disease markers at the single molecule level, enabling accurate diagnosis from bodily fluids such as urine and saliva. This versatile technology is designed for scalability to point-of-care applications, allowing for effective disease screening with a favorable cost structure. Amplified Sciences has developed a working prototype and has published proof of concept data, positioning itself to meet significant unmet medical needs in diagnostics. Founded in 2016 and based in West Lafayette, Indiana, the company was previously known as Nutrabiotix.

CenSyn is a brain health screening platform focused on enhancing the accessibility and efficiency of diagnosing various neurological conditions. The company has developed a handheld EEG monitoring device aimed at accelerating the screening process for Alzheimer's, traumatic brain injury, and epilepsy. Their proprietary software facilitates long-term management of brain health by allowing clinicians to wirelessly monitor and record brain electrical activity in real time. This innovative approach enables the rapid detection of altered mental status, supporting timely diagnosis and immediate treatment, ultimately reducing inpatient costs and improving care for diverse patient populations.

Case Western Reserve University, located in Cleveland's University Circle, is an independent research institution established in 1843. It encompasses various schools and colleges, including the School of Medicine, School of Law, Case School of Engineering, College of Arts and Sciences, Frances Payne Bolton School of Nursing, Mandel School of Applied Social Sciences, School of Dental Medicine, and Weatherhead School of Management. The university is known for its excellence in medical education and biomedical research, with the School of Medicine recognized for its contributions to medical discoveries and training future physicians. The School of Law offers nationally ranked programs in international law, health law, and intellectual property law, integrating leadership courses and practical experiences into its curriculum. Case Western Reserve University is a member of the Association of American Universities and maintains full accreditation from the Higher Learning Commission, reflecting its commitment to educational quality and research excellence.

Metfora is focused on developing a blood test designed to identify chronic lung and heart disorders, as well as cancers, in their early stages. The company employs artificial intelligence to analyze patterns in circulating metabolites within a patient's blood, enabling the detection of diseases that may not present significant symptoms initially. This innovative approach aims to assist both doctors and patients by providing timely insights for diagnosing serious health conditions, ultimately enhancing early intervention and treatment options.

Senseer Health, founded in 2017, focuses on addressing the chronic disease market by developing Smart Medical Device Therapies for managing various chronic conditions, which affect a significant portion of older adults. The company's innovations began with patented microsensors that monitor implantable devices for patients with hydrocephalus, renal, and cardiovascular diseases. To enhance the effectiveness of these microsensor-enabled devices, Senseer has incorporated advanced wearable and ambient sensor technologies. The integration of these multi-modal sensor technologies with an IoT software platform allows for the utilization of proprietary data sets and predictive analytics. This comprehensive approach provides healthcare providers with tools for remote monitoring and timely interventions, ultimately aiming to improve the quality of life for individuals with chronic conditions while reducing costs and enhancing patient safety.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Simmbion specializes in innovative therapeutic solutions by utilizing symbionts to manufacture therapeutic agents directly within the human body, effectively transforming it into a living pharmacy. This technology aims to eliminate the challenges associated with traditional therapy manufacturing, such as the need for complex production processes, repeated injections, and temperature-sensitive storage. By providing a single injection that lasts up to 12 weeks, Simmbion's approach addresses supply chain disruptions and enhances affordability and accessibility of cell therapies for diverse patient populations. Their adaptable and universally immune compatible systems focus on delivering biological drugs directly in vivo, supporting a patient-centric and outcome-driven healthcare model while minimizing the risks of infections and immune rejection.

Iaso Therapeutics, founded in 2018 and based in East Lansing, Michigan, is a biotechnology company focused on developing vaccines aimed at improving human health and treating infectious diseases. The company’s platform is dedicated to creating vaccines for serious illnesses, including smallpox, yellow fever, and tetanus. By providing healthcare professionals with innovative technologies, Iaso Therapeutics seeks to enhance public health outcomes and address critical health challenges.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Cytocybernetics is a biotechnology company that specializes in cellular electrophysiology. The company has developed the Cybercyte, a user-friendly plug-and-play dynamic clamp system designed for ease of use in research settings. In addition to its innovative products, Cytocybernetics offers a comprehensive range of contract research organization (CRO) services, which include FDA-mandated drug safety screening, custom electrophysiology, custom modeling, and custom analysis. These services are aimed at assisting clients in the development and evaluation of various cellular products, ensuring that they meet regulatory requirements and scientific standards.

Visicell Medical is a company focused on developing innovative medical imaging technology that enhances the early detection and diagnosis of diseases. It specializes in creating safe and biodegradable stem cell tracking tools, which facilitate real-time monitoring of stem cells implanted in patients. These tools are designed for use in both clinical and pre-clinical settings, allowing healthcare professionals to track stem cell progress effectively. In addition to stem cell tracking, Visicell Medical offers specialized image capture systems and analysis tools that provide high-resolution, three-dimensional views of tissues and cells. This technology aids in the identification of abnormalities, enabling earlier intervention and improved treatment outcomes for patients, while also aiming to reduce overall healthcare costs.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

Nostopharma specializes in developing treatments for pathologic bone growth, aiming to prevent rare bone diseases and minimize complications from traumatic injuries. The company offers a nanoparticle drug delivery system that addresses soft tissue trauma complications, facilitating the formation of new bone after surgeries, burns, and other traumatic incidents. By enhancing the recovery process, Nostopharma's innovative approach supports healthcare providers in improving clinical outcomes for patients undergoing surgical procedures related to post-traumatic injuries. Additionally, the company's efforts contribute to reducing rehabilitation costs for society.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company focuses on creating innovative vaccines, with its primary product being a universal influenza vaccine aimed at preventing pandemics. Utilizing a proprietary platform, InvVax's technology analyzes influenza proteins to address virus mutations, thereby enhancing the effectiveness of vaccines. In addition to its work on influenza, InvVax is exploring vaccine candidates for other viral infections, including HIV, Hepatitis B, and Hepatitis C.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

Oncurie develops targeted radionuclide therapy to create a cure for metastatic cancer through the use of novel molecular radionuclide technology, enabling healthcare providers to cure their patients. They are creating the technology to deliver radionuclides selectively to metastatic tissues.

Vulcan Biologics is a biotechnology company based in Irvine, California, established in 2019. It specializes in the modulation of the microbiome through the use of bacteriophages, which are viruses that specifically infect bacteria without harming human cells. This innovative platform aims to achieve stable and persistent changes in the gut microbiome, facilitating the treatment of gluten-related disorders such as gluten sensitivity and celiac disease. By altering the composition of gut bacteria, Vulcan Biologics enables healthcare providers to offer targeted therapeutic solutions for individuals affected by these conditions.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Aspero Medical focuses on improving gastrointestinal balloon endoscopy for the patient and physician. Our technology enhances device performance, saving time and money, while improving patient outcomes.

Clairways provides smart lung monitoring for pharmaceutical clinical trials. Clairways' wearable lung function monitor captures all of the most important respiratory metrics for people suffering from asthma, COPD, CF, or other chronic respiratory diseases.

xMD Diagnostics, based in Annapolis, Maryland, specializes in biotechnology within the healthcare sector. The company develops molecular diagnostics tools that use high-throughput microdissection technology to improve cancer diagnosis and management. These tools are designed to isolate, procure, and enrich cells of interest from biopsy and other specimen samples. This process facilitates various downstream analyses, including PCR, genomic or proteomic testing, and next-generation sequencing. By enhancing the capabilities of clinical and research laboratories, xMD Diagnostics supports pathologists, oncologists, and other healthcare professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

TheraCea Pharma is a biotechnology company based in Tucson that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that enables efficient and rapid fluorine-18 radiolabeling of biomolecules. This innovative approach supports both clinical and research applications, particularly in the context of neurological conditions. TheraCea Pharma's treatments aim to counteract dyskinesia, a side effect commonly associated with L-dopa, the standard treatment for Parkinson's disease. By providing new diagnostic agents, the company enhances medical professionals' capabilities in detecting not only neurological disorders but also cancer, thereby contributing to improved healthcare outcomes.

ZelosDx specializes in the development of blood testing products aimed at advancing research in brain health and diseases. The company provides researchers with access to proprietary technology that can be licensed and adapted for blood testing kits and automated laboratory equipment. Additionally, it offers pharmaceutical collaborators biomarker technology to support drug discovery efforts. By delivering critical data for diagnosis, monitoring, and evaluating therapeutic responses, ZelosDx facilitates significant advancements in the understanding and treatment of brain-related conditions.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

Paramita Therapeutics is a biotech company established in 2018 and based in San Diego, California. The company is dedicated to developing innovative therapeutics for cancer and infectious diseases. It specializes in efficiently transitioning new therapeutics into clinical settings using a patented, multifunctional chemical platform. This approach allows Paramita Therapeutics to create multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles. By leveraging its expertise, the company aims to provide patients with access to effective cancer treatments and dual-function therapeutic and vaccine products.

ALSUS MEDICAL offers treatment for urinary stream problems that may be weak or stop and start. In some cases, it can lead to infection, bladder stones, and reduced kidney function. They offer treatments that include medication that relaxes or shrinks the prostate, surgery, and minimally invasive surgery.

Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases.

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.

VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing disease-specific biosimulation models to enhance drug development processes. Founded in 2017, the company utilizes its proprietary BIOiSIM platform to predict the clinical outcomes of new drugs prior to clinical trials, thereby replacing traditional animal testing methods. By employing artificial intelligence, VeriSIM Life aims to improve the accuracy and efficiency of drug development, ultimately contributing to personalized healthcare solutions. Their offerings are tailored to meet the needs of both pre-clinical and clinical programs, focusing on small molecules, large molecules, and viruses to facilitate better treatment options and increase human life expectancy.

Progenitor MDX is engaged in developing cellular immunotherapy technologies that facilitate the creation of induced pluripotent stem cells for use in immune-oncology and engineered cell therapies. The company combines all Yamanaka factors into a single vector, enabling simple and reliable cellular reprogramming. This innovation supports the efficient production of allogeneic off-the-shelf CAR constructs derived from various cell sources. In addition to its focus on cellular immunotherapy, Progenitor MDX offers a comprehensive and customizable solution for managing COVID-19 infections, which includes providing testing results and actionable plans for infection management to support community health.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

Ionica Sciences, Inc. is focused on developing a spectroscopy-based diagnostic platform that utilizes surface enhanced Raman scattering (SERS) technology. Founded in 2013 and headquartered in Ithaca, New York, the company aims to address urgent needs in clinical diagnostics by enabling rapid and accurate identification of vector-borne, sexually transmitted, and neurological diseases. Ionica Sciences is particularly dedicated to creating in-vitro diagnostic assays for Lyme disease and other infectious conditions, allowing medical professionals to detect biologically relevant targets such as pathogens and hormones. By improving diagnostic accuracy, the company seeks to reduce patient suffering, minimize unnecessary antibiotic use, and lower healthcare costs associated with misdiagnoses.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

Omnicyte is a biotechnology company that develops targeted treatments for cancer therapy. The company develops a proprietary Immuno-Oncology Platform Technology for recombinant targeted immunomodulators, ovarian cancer indication, small cell lung cancer, and multiple additional indications.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

ForCast Orthopedics provides periprosthetic joint infection treatments using targeted medicine administration to enhance patient outcomes after joint replacement.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

Radiologics specializes in clinical research and medical imaging, offering software and clinical trial services. The company has developed a clinical trial software platform that facilitates image data management for clinical trials. This platform includes features such as file transfer and verification, integration with clinical data, automation of image processing routines, and connectivity solutions. By providing these tools, Radiologics supports health professionals in enhancing clinical research and improving diagnostic processes.

Prime Labs is a company focused on enhancing drug discovery through its cloud-based software platform, which specializes in mass spectrometry data processing, analysis, reporting, and visualization. The software is designed to support a variety of instruments and workflows, enabling scientists to conduct experiments with greater accuracy and efficiency. By streamlining the data processing experience, Prime Labs offers a user-friendly solution that minimizes the complexity typically associated with such tasks, allowing researchers to focus on their work with minimal training or installation requirements. This innovative approach facilitates a broader range of experiments in a shorter time frame, ultimately contributing to advancements in medical research and drug development.

Vitanova Biomedical is an early-stage biotechnology company based in Kerrville, Texas, dedicated to developing innovative cancer therapies that utilize Light-Activated Intracellular Acidosis (LAIA). Founded in 2015 by Matt Gdovin and Greg Espenhover, the company aims to enhance the quality of life for cancer patients and healthcare professionals by providing effective treatments that minimize side effects. Vitanova's approach leverages energy-based techniques that activate cancer-specific intracellular acidosis through targeted wavelengths of light and nanoparticles, which are designed to selectively target cancer cells using antibody or antigen conjugation. This strategy not only offers a cost-effective solution for cancer therapy but also seeks to improve patient outcomes in a transformative manner.

Caza Health is a biotech company specializing in the microbiome, immunology, and oncology. The company was founded in 2019 and is headquartered in Earlysville, Virginia.

Aspero Medical focuses on improving gastrointestinal balloon endoscopy for the patient and physician. Our technology enhances device performance, saving time and money, while improving patient outcomes.

Biocogniv Inc. specializes in developing artificial intelligence-powered diagnostic tools designed for hospitals, with a focus on enhancing clinical operations. Founded in 2019 and based in Burlington, Vermont, the company provides plugins for electronic health record (EHR) systems that enable real-time screening of patients for conditions such as COVID-19 by analyzing standard blood test results. Biocogniv's platform is particularly beneficial for emergency departments, as it can predict sepsis-related mortality and the need for intensive care unit admission. By leveraging the vast amounts of clinical and administrative data generated by hospitals, Biocogniv aims to improve the quality, cost, and accessibility of healthcare while facilitating accurate and non-invasive diagnostic methods.

Oscillo Biosciences focuses on developing innovative pharmacological treatments for Alzheimer's disease and related disorders. The company has conducted studies to assess the impact of music and multisensory stimulation on brain activity in adults. Oscillo Biosciences creates a prescription medical device and a digital therapeutic that work in tandem to restore healthy brain function in patients experiencing mild cognitive impairment and Alzheimer's disease. Their approach is grounded in the understanding that brain rhythms essential for memory and cognition are disrupted in these patients. Additionally, Oscillo Biosciences develops human-centered technologies aimed at rehabilitating individuals with language, cognitive, and motor impairments, utilizing rhythmic behaviors associated with speech, music, and movement to create effective therapies.

A biomarker test to diagnose a common and life-threatening bowel disease in preterm infants. It offers more accurate results than current options and allows earlier medical intervention.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

AxonDx is a company focused on the detection of circulating tumor cells (CTCs) in blood samples, which serve as a crucial indicator of both primary tumors and potential metastases. Their innovative nCYTE™ technology allows for the rapid scanning of un-enriched blood samples, identifying all classes of CTCs shed by solid tumors within minutes. This method not only enhances the accuracy of detection but also provides detailed morphological and molecular characterization of the identified cells. By enabling faster and more comprehensive insights into a patient’s cancer status, AxonDx's solutions support personalized medical treatment and early cancer detection. The company operates on a “razor and blade” business model, selling nCYTE™ instruments and associated diagnostic kits, making their technology accessible at the point of care. This advancement represents a significant improvement over existing CTC detection methods, which are often slow, costly, and less sensitive.

Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases.

LEAH Labs provides Car T cells for curing B-cell lymphoma cancer in dogs. Scientists at LEAH Labs use precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR) in order to create CAR T cells that seek out, specifically recognize, and destroy B cell lymphoma without the off-target side effects that come with chemotherapy.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Viora Health is a health and wellness company focused on advancing health equity among diverse populations. It offers tech-enabled, human-centered programs that utilize social and behavioral engagement to enhance capacity, satisfaction, outcomes, and revenue for healthcare providers. The company is backed by funding from reputable organizations such as the American Heart Association, the National Institutes of Health, Johnson and Johnson, and the National Science Foundation, with its initiatives validated through an Institutional Review Board-approved study. Viora Health's programs have demonstrated a 75% satisfaction score, double retention rates, and improved health outcomes, including reduced stress and better access to food and social support. Additionally, Viora Health develops a healthcare compliance platform aimed at enhancing adherence to diabetes prevention initiatives by connecting patients to programs, tracking data, and facilitating online engagement tools, which help diabetes prevention programs comply with insurance requirements and achieve outcome-based reimbursement.

Capienda Biotech focuses on enhancing the drug discovery process by providing an innovative biotechnology platform that significantly reduces the time and cost associated with developing new medicines. By addressing a critical bottleneck in drug discovery, Capienda's advanced bioanalytical system allows for faster and more efficient designs of small molecules, which results in higher quality drugs entering clinical trials. Their high-throughput kinetics system offers a throughput 48 times greater than traditional methods, eliminating the need for specialist scientists. The company's offerings include a laboratory instrument system and assay chemicals, creating a recurring revenue model that supports ongoing research and development efforts.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

VitalFlo Inc. is a digital health company based in Raleigh, North Carolina, established in 2017. It specializes in manufacturing handheld spirometers for asthmatic patients, allowing them to monitor their lung health and medication use. In addition to the spirometers, VitalFlo develops software that connects patients with chronic respiratory conditions to their healthcare providers. The company's remote monitoring system tracks lung function and environmental factors that may trigger asthma attacks, providing actionable insights to clinical teams. This innovative approach aims to reduce emergency room visits by offering timely recommendations to patients, thereby redefining asthma management and enhancing overall care.

Prime Labs is a company focused on enhancing drug discovery through its cloud-based software platform, which specializes in mass spectrometry data processing, analysis, reporting, and visualization. The software is designed to support a variety of instruments and workflows, enabling scientists to conduct experiments with greater accuracy and efficiency. By streamlining the data processing experience, Prime Labs offers a user-friendly solution that minimizes the complexity typically associated with such tasks, allowing researchers to focus on their work with minimal training or installation requirements. This innovative approach facilitates a broader range of experiments in a shorter time frame, ultimately contributing to advancements in medical research and drug development.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Senseer Health, founded in 2017, focuses on addressing the chronic disease market by developing Smart Medical Device Therapies for managing various chronic conditions, which affect a significant portion of older adults. The company's innovations began with patented microsensors that monitor implantable devices for patients with hydrocephalus, renal, and cardiovascular diseases. To enhance the effectiveness of these microsensor-enabled devices, Senseer has incorporated advanced wearable and ambient sensor technologies. The integration of these multi-modal sensor technologies with an IoT software platform allows for the utilization of proprietary data sets and predictive analytics. This comprehensive approach provides healthcare providers with tools for remote monitoring and timely interventions, ultimately aiming to improve the quality of life for individuals with chronic conditions while reducing costs and enhancing patient safety.

Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions. Founded in 2017 and headquartered in Solana Beach, California, the company is advancing its lead program aimed at treating Friedreich’s ataxia. Additionally, Design Therapeutics is exploring treatments for other conditions such as Fragile X syndrome and myotonic dystrophy, utilizing its proprietary GeneTACTM technology, which involves small-molecule gene-targeted therapeutics designed to modify the underlying causes of these inherited diseases. The company is committed to addressing serious monogenic disorders driven by nucleotide repeat mutations through its ongoing research and development efforts.

Iaso Therapeutics, founded in 2018 and based in East Lansing, Michigan, is a biotechnology company focused on developing vaccines aimed at improving human health and treating infectious diseases. The company’s platform is dedicated to creating vaccines for serious illnesses, including smallpox, yellow fever, and tetanus. By providing healthcare professionals with innovative technologies, Iaso Therapeutics seeks to enhance public health outcomes and address critical health challenges.

Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.

Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Abalone Bio, Inc. is a biotechnology company based in Richmond, California, established in 2017. The company specializes in developing full-spectrum antibody drugs aimed at treating various conditions, including pain, inflammatory diseases, rare cancers, and rare kidney diseases. One of its primary focuses is on creating a drug for peripheral neuropathy. Abalone Bio employs innovative techniques that utilize libraries of yeast cells expressing antibody variants to either activate or inhibit specific drug targets, facilitating the production of recombinant protein versions of its antibodies. This approach allows for the confirmation of their efficacy through human cell assays, ultimately enabling medical practitioners to address rare diseases more effectively.

Sanguine is focused on enhancing translational biomedical research by facilitating patient participation. The company offers tools and concierge services that enable patients to engage in medical research from the comfort of their homes, promoting transparency and communication throughout the process. By prioritizing respectful patient support and appropriate compensation, Sanguine aims to improve the overall patient experience and ensure that research biospecimens are more impactful. Through these efforts, Sanguine seeks to bridge the gap between patients and researchers, empowering individuals to contribute directly to the development of personalized medicines and new treatments.

Trilo Therapeutics, based in San Francisco and founded by experienced professionals in the biotech and pharmaceutical sectors, focuses on developing innovative peptide-drug conjugates (PDCs) to overcome the limitations of current antibody-drug conjugates (ADCs). The company employs macrocyclic D-amino acid peptides to replace the antibody component, resulting in superior tumor penetration and reduced toxicity compared to traditional L-amino acid peptide-drug conjugates. Trilo's conjugates are designed to be compatible with clinically validated payloads and radionuclides, facilitating new treatment modalities through a "fast in/fast out" mechanism. Additionally, Trilo is engaged in creating novel inhibitors of protein interactions, aiming to target disease-causing proteins for the treatment of cancer, autoimmune disorders, and infectious diseases. This dual focus on peptide-based therapies and protein interaction inhibitors positions Trilo Therapeutics as a leader in developing effective treatments for severe medical conditions.

TEGA was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. They aim to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. Their work is motivated by a commitment to innovation and helping patients. They combine their powerful insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Rumi Scientific is a research-oriented company focused on developing innovative medications and treatments for genetic disorders affecting the central nervous system, particularly Huntington's Disease. The company utilizes a proprietary human organoid platform that simulates human development in vitro, integrating gene editing techniques with multi-cellular self-organization to create defined diseased embryonic tissues. This advanced platform facilitates drug discovery and high-throughput screening, leveraging artificial intelligence to identify potential treatments. By emphasizing synthetic human embryology in both healthy and diseased contexts, Rumi Scientific aims to advance therapeutic options for numerous genetic conditions that currently lack effective cures. The company's approach combines single-cell, time-lapse imaging with customized analytic tools, resulting in a more efficient and cost-effective drug development process that enhances treatment success rates and outcomes for patients.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Harmonic Bionics, founded in 2016 and based in Austin, Texas, is focused on transforming neurorehabilitation through advanced robotic technology aimed at enhancing patient recovery. The company develops an upper body robotic rehabilitation and assessment system specifically designed for shoulder care, utilizing biomechanically matched designs and high-speed sensors to generate precise data. This innovative approach allows medical professionals to establish standardized, automated therapy protocols, thereby improving the efficiency and effectiveness of physical medicine and rehabilitation.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Tanzen Medical, founded in 2017 and located in Severna Park, Maryland, specializes in the development of clinically accurate wearable devices aimed at assessing and enhancing sleep quality in a home setting. The company's innovative technology is designed to aid in the diagnosis of sleep-related disorders, such as ADHD and narcolepsy, by monitoring nightly leg movements. This functionality allows users to track various aspects of their sleep, including quality, position, and arousal, ultimately promoting better sleep health.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Vanguard Medical Technologies is developing and commercializing cutting-edge healthcare products to address critical healthcare needs. They are maintaining ethical standards by improving outcomes, reducing overall healthcare costs, and causing no harm to humans or animals.

Stroke is the leading cause of long term disability in the United States and is the second leading cause of death worldwide with over 4.4 million deaths a year. It affects over 700,000 patients every year in the United States alone.

Plasmonic Diagnostics is a biotechnology company focused on developing innovative diagnostic systems for infectious diseases, sexually transmitted infections, and cancer. Utilizing advanced single molecule detection technology, the company aims to create non-invasive and highly sensitive testing devices that target specific biomarkers. Their offerings include 3D-printed components and a smartphone camera as a detector, allowing for efficient time-to-detection, intrinsic signal amplification, and a high signal-to-noise ratio. This approach not only enhances the accuracy of diagnostics but also aims to make testing more affordable and accessible for patients.

Enable Biosciences is a biotechnology company focused on developing ultrasensitive tests for various diseases, including HIV and type 1 diabetes. The company creates advanced immunoassays that allow for the early detection and treatment of autoimmune and infectious diseases. By providing sensitive antibody detection, Enable Biosciences aims to facilitate early diagnosis and precise monitoring of challenging conditions, such as Lyme disease, ultimately improving patient outcomes through timely intervention.

BioSyntagma is a precision medicine company focused on enhancing cancer treatment through an innovative microfluidic platform. The company generates comprehensive multi-omic and spatial profiles of tissues, allowing for a thorough understanding of cancer in individual patients. This detailed profiling enables clinicians to match patients with appropriate therapies and recommend treatment plans that help prevent acquired drug resistance. By leveraging artificial intelligence, BioSyntagma aims to advance the implementation of precision medicine, supporting both healthcare providers and drug developers in delivering personalized cancer care.

VitalFlo Inc. is a digital health company based in Raleigh, North Carolina, established in 2017. It specializes in manufacturing handheld spirometers for asthmatic patients, allowing them to monitor their lung health and medication use. In addition to the spirometers, VitalFlo develops software that connects patients with chronic respiratory conditions to their healthcare providers. The company's remote monitoring system tracks lung function and environmental factors that may trigger asthma attacks, providing actionable insights to clinical teams. This innovative approach aims to reduce emergency room visits by offering timely recommendations to patients, thereby redefining asthma management and enhancing overall care.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

BIDEA offers tests that will not only impact the quality of life of patients but can also reduce costs to hospitals, health insurance companies, and government agencies. Their proposed screening technology is expected to help gynaecologists in hospitals and in private practices provide a complete diagnosis in less time, reducing the number of visits and endometrial cancer incidence through early detection, especially in women over the age of 50.

Chemeleon has developed an innovative diagnostic platform that provides rapid, accurate, and affordable detection of a wide array of analytes, including drugs, proteins, and viruses. This proprietary in vitro diagnostic technology delivers a colorimetric readout within minutes, visible to the naked eye, without requiring reagents, instruments, or specialized training. This capability facilitates decentralized testing, allowing clinicians to extend point-of-care diagnostics and enabling individuals to self-administer tests at the point of need. By combining selective molecular receptors with colorimetric nanomaterial reporters, Chemeleon's diagnostics offer immediate and actionable results, significantly improving patient outcomes while reducing costs. Notably, under a National Institutes of Health grant, the company created a test to detect beta-2-transferrin, aiding healthcare providers in promptly diagnosing cerebrospinal fluid leaks, which can drastically lower morbidity and patient stay duration. This technology meets the World Health Organization's ASSURED criteria, making it suitable for both advanced healthcare settings and resource-limited environments, thereby revolutionizing the accessibility of critical diagnostic services.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

PathoVax is a biotech start-up from Johns Hopkins commercializing RGVax, the world’s first low-cost Human Papillomavirus (HPV) vaccine targeting all clinically relevant types. Current vaccines target some cancer-causing HPVs and only focus on sexual transmitted types, resulting in low uptake due to the incomplete coverage and social stigma. Established animal studies have confirmed RGVax’s protection against all 15 oncogenic types and the added coverage against skin HPVs positions RGVax as a childhood vaccine, allowing unrivalled early market entry in a segment with superior uptake.

Harmonic Bionics, founded in 2016 and based in Austin, Texas, is focused on transforming neurorehabilitation through advanced robotic technology aimed at enhancing patient recovery. The company develops an upper body robotic rehabilitation and assessment system specifically designed for shoulder care, utilizing biomechanically matched designs and high-speed sensors to generate precise data. This innovative approach allows medical professionals to establish standardized, automated therapy protocols, thereby improving the efficiency and effectiveness of physical medicine and rehabilitation.

Glyscend Therapeutics is focused on developing innovative treatments for type 2 diabetes, drawing inspiration from the metabolic benefits observed in bariatric surgery. The company has created a non-invasive, orally ingestible intestinal coating designed to replicate the effects of surgery by preventing stimulation of the duodenal mucosa and inhibiting crucial neurohormonal pathways in the proximal gut. This novel approach aims to provide patients with effective glucose control while minimizing side effects such as weight gain and hypoglycemia. Glyscend also seeks to equip endocrinologists and primary care physicians with advanced tools to treat diabetes more effectively, rather than merely managing the condition. Founded in 2014 by Ashish Nimgaonkar, Michael Parlato, and Pratik Patel, Glyscend is committed to enhancing the care pathway for individuals living with type 2 diabetes.

Accelevir Diagnostics is a biotech-based industry. They provide clinical researches like unparalleled virology and infectious disease expertise to clinical, biotech, pharmaceutical, public health, academic, and diagnostic partners. They provide scientifically-driven custom services. They include digital PCR, single-target culture techniques, fidelity sequencing, and data-driven analytics.

Sepragen Corporation, located in Hayward, California, specializes in providing innovative products and processes tailored for the biotechnology and nutraceutical sectors. The company focuses on enhancing productivity while minimizing space requirements, allowing for efficient and predictable scaling of processes from laboratory settings to full production. Their offerings, which include chromatography columns, packing systems, and bioreactors, are designed for compliance with high-quality standards and traceability, ensuring they meet cGMP requirements. Sepragen supports its clients with comprehensive documentation and validation services, contributing to the development of numerous FDA-approved drugs globally. Additionally, the company has patented methods for isolating proteins from dairy whey and removing impurities from various sources. With an expanded manufacturing presence in India and a growing network of distributors, Sepragen continues to broaden its impact in the industry.